Back to today’s briefing

Story perspectives

Hims & Hers Shares Plunge 8% After FDA Ruling

3/8/2025

23 3

Summary

Story summary

Hims & Hers (HIMS.US) faced a nearly 8% plunge in shares as a court upheld the FDA's ruling to take Zepbound off the shortage list, curbing the company's ability to market alternatives to popular drugs like Ozempic and Wegovy. With a staggering 46% decline since semaglutide's removal, the tele-pharmacy grapples with mounting hurdles.

1 of 1

Story summary

Hims & Hers (HIMS.US) faced a nearly 8% plunge in shares as a court upheld the FDA's ruling to take Zepbound off the shortage list, curbing the company's ability to market alternatives to popular drugs like Ozempic and Wegovy. With a staggering 46% decline since semaglutide's removal, the tele-pharmacy grapples with mounting hurdles.